CURRENT DRUG METABOLISM

Scope & Guideline

Shaping the Future of Drug Development and Safety

Introduction

Delve into the academic richness of CURRENT DRUG METABOLISM with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1389-2002
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 2000 to 2024
AbbreviationCURR DRUG METAB / Curr. Drug Metab.
Frequency14 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

CURRENT DRUG METABOLISM focuses on the comprehensive understanding of drug metabolism, pharmacokinetics, and their implications in therapeutic efficacy and safety. The journal emphasizes innovative methodologies and interdisciplinary approaches in drug development and metabolism research.
  1. Drug Metabolism Mechanisms:
    Exploration of the biochemical processes involved in drug metabolism, including the roles of enzymes like cytochrome P450, phase I and phase II reactions, and genetic polymorphisms affecting drug metabolism.
  2. Pharmacokinetics and Drug Interaction Studies:
    Investigation of the absorption, distribution, metabolism, and excretion (ADME) of drugs, including studies on drug-drug interactions and their clinical implications.
  3. Innovative Drug Delivery Systems:
    Research on novel drug delivery methods, including nanotechnology and biomimetic systems, aimed at improving therapeutic outcomes and targeting specific tissues or cells.
  4. Pharmacogenomics and Personalized Medicine:
    Examination of how genetic variations affect individual responses to drugs, with implications for personalized treatment strategies and drug development.
  5. Environmental and Physiological Influences on Drug Metabolism:
    Studies investigating how external factors like altitude, diet, and microbiota interactions influence drug metabolism and pharmacokinetics.
The journal has identified several emerging themes reflecting current trends in drug metabolism research, highlighting areas of increasing interest and relevance for the scientific community.
  1. Nanotechnology in Drug Delivery:
    There is a growing body of work focused on the application of nanotechnology for drug delivery systems, which aim to enhance the bioavailability and targeting of therapeutics.
  2. Machine Learning and AI in Pharmacokinetics:
    The incorporation of machine learning and artificial intelligence in predicting drug metabolism and pharmacokinetics is increasingly prominent, showcasing the potential for computational tools in drug development.
  3. Impact of Gut Microbiota on Drug Metabolism:
    Research exploring the role of gut microbiota in modulating drug metabolism and pharmacokinetics is gaining traction, emphasizing the importance of microbiome interactions in therapeutic outcomes.
  4. Environmental Pharmacology:
    Emerging studies examine the effects of environmental factors, such as altitude and pollution, on drug metabolism and pharmacokinetics, reflecting a broader interest in how external environments influence drug actions.

Declining or Waning

While CURRENT DRUG METABOLISM maintains a broad scope, some themes have shown a decline in publication frequency. This may indicate shifting research priorities or saturation of existing knowledge in these areas.
  1. Traditional Herbal Medicine Interactions:
    Research on the interactions between herbal medicines and conventional drugs has decreased, possibly due to a growing emphasis on clinical pharmacology and evidence-based studies.
  2. Basic Mechanistic Studies of Drug Metabolism:
    There appears to be a waning interest in purely mechanistic studies without translational applications, as the focus shifts toward clinically relevant findings and implications.
  3. In vitro Metabolism Studies:
    The frequency of in vitro studies using liver microsomes or cell lines has declined, as researchers increasingly prefer in vivo studies or physiologically-based pharmacokinetic (PBPK) modeling that provide more clinically relevant data.

Similar Journals

XENOBIOTICA

Unveiling the Complexities of Xenobiotic Interactions.
Publisher: TAYLOR & FRANCIS LTDISSN: 0049-8254Frequency: 12 issues/year

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

BMC Pharmacology & Toxicology

Advancing knowledge in pharmacology and toxicology.
Publisher: BMCISSN: Frequency: 1 issue/year

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

DRUG METABOLISM REVIEWS

Exploring the intricacies of drug metabolism.
Publisher: TAYLOR & FRANCIS LTDISSN: 0360-2532Frequency: 4 issues/year

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Delivering High-Impact Research for Healthcare Professionals
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Current Pharmaceutical Analysis

Advancing the Frontiers of Pharmaceutical Research
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4129Frequency: 6 issues/year

Current Pharmaceutical Analysis, published by Bentham Science Publishers Ltd, is a vital resource for professionals and researchers in the fields of Pharmaceutical Science, Biochemistry, and Molecular Medicine. Established in 2006, this peer-reviewed journal aims to provide a platform for the latest advancements and analytical methodologies in pharmaceutical research and drug development. Over the years, it has garnered attention for its rigorous scrutiny and contributions to the landscape of pharmacology, evidenced by its quartile placements in various categories, most notably Q3 in Pharmaceutical Science. Despite its current rankings placing it in the lower quartile in several disciplines, the journal remains an essential venue for both emerging and established researchers seeking to disseminate their findings. With the widespread accessibility of its articles, researchers, professionals, and students can engage with cutting-edge studies to foster innovation in pharmaceutical analysis. For access to the latest research contributions, readers can explore the digital archive and stay updated on pivotal discussions shaping the future of the pharmaceutical sciences.

BIOCHEMICAL PHARMACOLOGY

Leading the way in biochemical pharmacology research.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0006-2952Frequency: 12 issues/year

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

DRUG METABOLISM AND DISPOSITION

Exploring the Frontiers of Pharmacology
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0090-9556Frequency: 12 issues/year

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.

CLINICAL PHARMACOKINETICS

Exploring Clinical Insights in Pharmacokinetics
Publisher: ADIS INT LTDISSN: 0312-5963Frequency: 12 issues/year

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

DRUGS IN R&D

Connecting researchers for a healthier tomorrow.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

INDIAN JOURNAL OF PHARMACOLOGY

Innovating drug action insights to enhance therapeutic practices.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.